In breast cancer xenograft models with activating mutations in the ESR1, as well as tamoxifen-sensitive and tamoxifen-resistant breast cancer xenografts, GDC-0810 demonstrates potent anti-tumor activity [50, 51]. The gene discussed is ESR1; the disease is neoplasm.